OOIR: Observatory of International Research

Papers

(The TQCC of Current Opinion in Nephrology and Hypertension is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Acute kidney injury and maladaptive tubular repair leading to renal fibrosis	71
The glomerular crescent	47
The role of uric acid in inflammasome-mediated kidney injury	45
Pharmacologic and psychological interventions for depression treatment in patients with kidney disease	43
Cystatin C is ready for clinical use	38
Advances in exercise therapy in predialysis chronic kidney disease, hemodialysis, peritoneal dialysis, and kidney transplantation	34
Membranous nephropathy: current understanding of various causes in light of new target antigens	28
The varying roles of macrophages in kidney injury and repair	27
Microbiome modulation as a novel therapeutic approach in chronic kidney disease	25
Pain management in patients with chronic kidney disease and end-stage kidney disease	24
Calciprotein particles: mineral behaving badly?	23
Applications of machine learning methods in kidney disease	21
Endothelin receptor antagonists for the treatment of diabetic and nondiabetic chronic kidney disease	20
Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease	19
Depression in dialysis	19
Artificial intelligence driven next-generation renal histomorphometry	18
Medical nutrition therapy using plant-focused low-protein meal plans for management of chronic kidney disease in diabetes	18
Current status of the assessment of sarcopenia, frailty, physical performance and functional status in chronic kidney disease patients	17
Novel conservative management of chronic kidney disease via dialysis-free interventions	17
Apolipoprotein L1: role in the evaluation of kidney transplant donors	17
Recent advances in the treatment of uremic pruritus	17
Disparities in chronic kidney disease-the state of the evidence	16
The « race » correction in estimating glomerular filtration rate: an European point of view	15
New insights into muscle function in chronic kidney disease and metabolic acidosis	15
Circadian rhythms of mineral metabolism in chronic kidney disease–mineral bone disorder	15

The genetic spectrum of Gitelman(-like) syndromes	15
Ageing, cellular senescence and chronic kidney disease: experimental evidence	14
How common is primary aldosteronism?	13
Sodium bicarbonate therapy for acute respiratory acidosis	12
Plasma and urine biomarkers in chronic kidney disease: closer to clinical application	12
Recent advances in dialysis membranes	12
Imaging of renal fibrosis	12
Precision medicine approach to dialysis including incremental and decremental dialysis regimens	12
Novel approach to unpleasant symptom clusters surrounding pruritus in patients with chronic kidney disease and on dialysis therapy	12
Chimerism and tolerance: past, present and future strategies to prolong renal allograft survival	12
Parietal epithelial cells role in repair versus scarring after glomerular injury	12
B-cell depletion or belimumab or voclosporin for lupus nephritis?	11
Epigenomics and the kidney	11
Novel approaches to management of hyperkalaemia in kidney transplantation	11
Screening for chronic kidney disease	11
Pathogenesis of coronavirus disease 2019-associated kidney injury	11
Cystic fibrosis in the kidney: new lessons from impaired renal HCO3− excretion	10
Kidney in the net of acute and long-haul coronavirus disease 2019: a potential role for lipid mediators in causing renal injury and fibrosis	10
Cardiovascular autonomic nervous system dysfunction in chronic kidney disease and end-stage kidney disease: disruption of the complementary forces	10
Gut microbiome, parathyroid hormone, and bone	10
Uric acid stone disease: lessons from recent human physiologic studies	10
Mitochondrial deacetylase Sirt3 in vascular dysfunction and hypertension	10
Stiripentol identifies a therapeutic target to reduce oxaluria	10
Hypernatremia in the intensive care unit	10
Lifestyle interventions for preventing and ameliorating CKD in primary and secondary care	9
Direct oral anticoagulants in chronic kidney disease: an update	9
Burosumab in X-linked hypophosphatemia and perspective for chronic kidney disease	9
Gut–brain–bone marrow axis in hypertension	9
Diagnosis of amyloid beyond Congo red	9
Molecular regulation and function of FoxO3 in chronic kidney disease	9
TaleNeprilysin and Neprilysin inhibition in chronic kidney disease	9
Tubular effects of sodium–glucose cotransporter 2 inhibitors: intended and unintended consequences	9
Novel intestinal dialysis interventions and microbiome modulation to control uremia	9
Contribution of Th17 cells to tissue injury in hypertension	9
The clinical application of frailty in nephrology and transplantation	9
Coronavirus disease 2019 and kidney injury	8
GFR slope as a surrogate endpoint for CKD progression in clinical trials	8
Fibroblast growth factor receptor as a potential candidate for phosphate sensing	8
Fluid administration strategies for the prevention of contrast-associated acute kidney injury	8
Managing hyperuricemia and gout in chronic kidney disease: a clinical conundrum	8
Mechanisms of leptin-induced endothelial dysfunction	8
The epidermal growth factor receptor axis and kidney fibrosis	8
Novel approaches to sarcopenic obesity and weight management before and after kidney transplantation	8
Cardiovascular disease in children with chronic kidney disease	8
Application of dynamic contrast enhanced ultrasound in the assessment of kidney diseases	8
The potential of artificial intelligence-based applications in kidney pathology	8
Editorial: Novel therapeutic approaches in chronic kidney disease, uremia and kidney transplantation: past, present and future	7
The quest for cardiovascular disease risk prediction models in patients with nondialysis chronic kidney disease	7
Angiotensin-converting enzyme 2: from a vasoactive peptide to the gatekeeper of a global pandemic	7
Cellular therapies in kidney transplantation	7

SNF472: mechanism of action and results from clinical trials	7
Actions of immune cells in the hypertensive kidney	7
Extracellular vesicles: a novel window into kidney function and disease	7
More precise donor–recipient matching: the role of eplet matching	7
Neglected analytes in the 24-h urine: ammonium and sulfate	7
The impact of advanced glycation end products on bone properties in chronic kidney disease	7
Apolipoprotein L1 and mechanisms of kidney disease susceptibility	7
Regulation of renal pendrin activity by aldosterone	7
New therapeutics for primary hyperoxaluria type 1	7
Treatment potential in APOL1-associated nephropathy	7
Emerging non-pharmacological interventions in ADPKD: an update on dietary advices for clinical practice	7
Role of inwardly rectifying K+ channel 5.1 (Kir5.1) in the regulation of renal membrane transport	6
Novel approaches to hypoglycemia and burnt-out diabetes in chronic kidney disease	6
Kidney dysfunction requiring dialysis is a heterogeneous syndrome: we should treat it like one	6
Communication principles and practices for making shared decisions about renal replacement therapy: a review of the literature	6
Recent evidence on the effect of urate-lowering treatment on the progression of kidney disease	6
Redlining has led to increasing rates of nephrolithiasis in minoritized populations: a hypothesis	6
Assessing physical function in chronic kidney disease	6
Novel management of diabetes in kidney transplantation	6
Role of deceased donor kidney procurement biopsies in organ allocation	6
Clinical utility of bone turnover markers in patients with chronic kidney disease	6
Intestinal phosphorus absorption: recent findings in translational and clinical research	6
Hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors: ready for primetime?	6
Sodium-glucose cotransporter 2 inhibition in non-diabetic kidney disease	6
Epithelial Na+ channel and the glycocalyx: a sweet and salty relationship for arterial shear stress sensing	6
Iron deficiency and iron therapy in heart failure and chronic kidney disease	6
Simultaneous management of disordered phosphate and iron homeostasis to correct fibroblast growth factor 23 and associated outcomes in chronic kidney disease	6
The role of PPARα in autosomal dominant polycystic kidney disease	6
Lipocalin-2: a novel link between the injured kidney and the bone	6
Role of artificial intelligence in the diagnosis and management of kidney disease: applications to chronic kidney disease and acute kidney injury	6
Intravitreal vascular endothelial growth factors hypertension, proteinuria, and renal injury: a concise review	6
Revisiting diuretic choice in chronic kidney disease	6